Market Place
Sourcing Support
All News #Library
Biotech
Intensity Receives Pinnacle Award For Healthcare Innovation
15 Apr 2026 //
PR NEWSWIRE
Intensity Therapeutics Reveals 2025 Financial Results
28 Mar 2026 //
PR NEWSWIRE
Intensity Therapeutics Bolsters IP Portfolio With New US Patent
24 Mar 2026 //
PR NEWSWIRE
Intensity Therapeutics Restores Nasdaq Bid Price Compliance
06 Mar 2026 //
PR NEWSWIRE
Intensity Therapeutics Announces Reverse Stock Split
13 Feb 2026 //
PR NEWSWIRE
Intensity Therapeutics Outlines 2025 Milestones, 2026 Goals
13 Jan 2026 //
PR NEWSWIRE
Intensity Therapeutics To Present 2 Posters At 2025 San Antonio
11 Dec 2025 //
PR NEWSWIRE
Intensity Therapeutics Announces Two Presentations at 2025 SABCS
04 Dec 2025 //
PR NEWSWIRE
Intensity Therapeutics Reveals Q3 2025 Financials & Corporate
06 Nov 2025 //
PR NEWSWIRE
Intensity Therapeutics Prices $4M Stock Offering
31 Oct 2025 //
PR NEWSWIRE
Intensity Therapeutics Reveals Clinical Results of INT230-6
30 Oct 2025 //
PR NEWSWIRE
Intensity Updates on INVINCIBLE-4, Triple-Negative Breast Cancer
10 Sep 2025 //
PR NEWSWIRE
Intensity Therapeutics Joins Chat at H.C. Wainwright Conference
02 Sep 2025 //
PR NEWSWIRE
Intensity Therapeutics, Inc. raises $6.6M from ATM stock sales
04 Aug 2025 //
PR NEWSWIRE
Intensity Therapeutics Reports Q1 2025 Financial Results
13 May 2025 //
PR NEWSWIRE
Intensity Therapeutics Selected for Oral Presentation at CTOS 2024
08 Nov 2024 //
PR NEWSWIRE
Cancer biotech Intensity Therapeutics looks to pull in $16M+ IPO
30 Jun 2023 //
ENDPTS
Intensity`s INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab
03 Jun 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.